The cytogenetic effect of triclabendazole an antihelminthic drug used for the treatment of human fascioliasis was evaluated in peripheral blood lymphocytes of 30 patients with fasciola hepatica before and after treatment with the drug. The number of cells with chromosomal aberrations and sister chromatid exchanges did not show any statistically significant differences in the patients either before treatment when compared to the control or after triclabendazole therapy [P2 0.05). Based on the results of the present study, our data indicate that infection with fasciola hepatica does not increase chromosomal aberrations or sister chromatid exchanges, and that the genotoxic effect of triclabendazole indicate that the drug is not a mutagenic agent and could be used safely in therapeutic doses for the treatment of human fascioliasis.
Mahrous, H., & Abou Hollo, S. (2003). Study of Cytogenetic Biomarkers in Human Fascioliasis and Triclabendazole Treatment. Journal of High Institute of Public Health, 33(1), 105-116. doi: 10.21608/jhiph.2003.199892
MLA
Hanan S. Mahrous; Sahar Abou Hollo. "Study of Cytogenetic Biomarkers in Human Fascioliasis and Triclabendazole Treatment", Journal of High Institute of Public Health, 33, 1, 2003, 105-116. doi: 10.21608/jhiph.2003.199892
HARVARD
Mahrous, H., Abou Hollo, S. (2003). 'Study of Cytogenetic Biomarkers in Human Fascioliasis and Triclabendazole Treatment', Journal of High Institute of Public Health, 33(1), pp. 105-116. doi: 10.21608/jhiph.2003.199892
VANCOUVER
Mahrous, H., Abou Hollo, S. Study of Cytogenetic Biomarkers in Human Fascioliasis and Triclabendazole Treatment. Journal of High Institute of Public Health, 2003; 33(1): 105-116. doi: 10.21608/jhiph.2003.199892
)
View on SCiNiTO